Clinical Scorecard: Risk Estimation Errors in Glaucoma Treatment

At a Glance

Key Highlights

• Glaucoma surgery prevents more blindness than it causes despite potential surgical risks.
• Physicians often overestimate small risks (e.g., surgery complications, PGA-induced CME) and underestimate larger risks (e.g., blindness from untreated glaucoma, noncompliance).
• Innovations in drug delivery and minimally invasive glaucoma surgeries (MIGS) are underutilized due to risk misperceptions.

Guideline-Based Recommendations

Diagnosis

• Assess intraocular pressure and visual field deterioration to guide treatment decisions.

Management

• Consider early and appropriately aggressive intervention to prevent irreversible vision loss.
• Use prostaglandin analogs (PGAs) without undue fear of cystoid macular edema (CME), as evidence shows no increased CME risk.
• Incorporate minimally invasive glaucoma surgeries (MIGS) when appropriate, recognizing transient complications like hyphema are generally manageable.

Monitoring & Follow-up

• Regularly monitor IOP and visual fields to evaluate disease progression and treatment efficacy.

Risks

• Avoid overestimating rare surgical complications leading to errors of omission.
• Avoid overestimating imaginary risks such as PGA-induced CME which may lead to under-treatment.
• Recognize the high risk of vision loss from noncompliance with medical therapy.

Patient & Prescribing Data

Glaucoma patients requiring IOP-lowering therapy

Large-scale data (~40,000 patients) show PGAs do not increase acute CME risk and may reduce it compared to other glaucoma medications.

Clinical Best Practices

• Balance risk estimation to avoid errors of omission (undertreatment) and commission (overtreatment).
• Educate patients on the importance of compliance with prescribed glaucoma therapies.
• Adopt new glaucoma treatment innovations judiciously, weighing transient complications against long-term benefits.
• Use evidence-based IOP targets (e.g., <14 mmHg per AGIS study) tailored to individual patient risk.

References

• The Advanced Glaucoma Intervention Study (AGIS): 7
• Incidence of acute cystoid macular edema after starting a prostaglandin analog